✦ LIBER ✦

Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis

✍ Scribed by Anneli Lauhio; Marjatta Leirisalo-Repo; Juhani Lähdevirta; Pekka Saikku; Heikki Repo

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 861 KB
Volume: 34
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.1780340103

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

No benefit of long-term ciprofloxacin tr

No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study

✍ Joachim Sieper; Claas Fendler; Sigrid Laitko; Helmut Sörensen; Christel Gripenbe 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB 👁 3 views

Alefacept in combination with methotrexa

Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study

✍ Philip J. Mease; Dafna D. Gladman; Edward C. Keystone 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act

Abatacept in the treatment of patients w

Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial

✍ Philip Mease; Mark C. Genovese; Geoffrey Gladstein; Alan J. Kivitz; Christopher 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 3 views

An oral Syk kinase inhibitor in the trea

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

✍ Mark C. Genovese; Arthur Kavanaugh; Michael E. Weinblatt; Charles Peterfy; Julie 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 2 views

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Very early treatment with infliximab in

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial

✍ Mark A. Quinn; Philip G. Conaghan; Philip J. O'Connor; Zunaid Karim; Adam Greens 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views